Pds biotech reports second quarter 2022 financial results and provides business update

Florham park, n.j., aug. 08, 2022 (globe newswire) -- pds biotechnology corporation (nasdaq: pdsb), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunotherapies and infectious disease vaccines based on the company's proprietary versamune® and infectimune™ t cell-activating technologies, will discuss its financial results for the quarter ended june 30, 2022 and provide a business update on its conference call today.
PDSB Ratings Summary
PDSB Quant Ranking